New York, United States:
Gross sales of the Covid-19 vaccine developed by Pfizer and BioNTech may attain as much as $15 billion in 2021 and go greater if Pfizer indicators further provide contracts, Pfizer mentioned Tuesday.
The projections got here as Pfizer projected full-year 2021 gross sales of between $59.four billion and $61.four billion, which means that about one-fourth of estimated complete gross sales will come from the Covid-19 vaccine.
The forecast displays “a continued restoration in macroeconomic and healthcare exercise all through 2021 as extra of the inhabitants turns into vaccinated towards Covid-19,” Pfizer mentioned.
“These assumptions are guided by the trajectory of present an infection charges in lots of components of the world and the anticipated timeline for broad entry to efficient vaccines.”
Pfizer reported fourth-quarter web earnings of $594 million, in contrast with a lack of $337 million within the year-ago interval.
For all of 2020, Pfizer reported earnings of $9.6 billion, down 41.four % from 2019, with revenues up two % to $41.9 billion.
Pfizer’s fourth-quarter revenues included $154 million in gross sales of the Covid-19 vaccine.
The vaccine started profitable approval from authorities late final yr. Pfizer mentioned it expects it may probably ship as much as 2 billion doses in 2021 based mostly on a number of elements, together with including extra suppliers and contract producers.
Shares of Pfizer rose 0.5 % to $35.94 in pre-market buying and selling.